A stable isotope tracer study revealed the physiological mechanism underlying obicetrapib's LDL-C lowering effects. The study demonstrated that obicetrapib reduced LDL-ApoB levels by substantially increasing the fractional catabolic rate (FCR) of LDL-ApoB-100.
Compared to placebo, obicetrapib significantly increased the FCR of LDL-ApoB-100 from 0.362 pools/day to 0.531 pools/day, representing a 54% increase (p=0.002). This indicates that obicetrapib promotes the removal of circulating LDL particles from the bloodstream.
Furthermore, obicetrapib treatment resulted in a mean 66% reduction in the concentration of small LDL particles, which are considered more atherogenic. These data complement existing preclinical and clinical evidence, conclusively supporting obicetrapib's mechanism of action for LDL-C lowering.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.